At Philips, our global vision is to improve the lives of 3 billion people a year by 2025 through the introduction of groundbreaking innovations across the healthcare continuum. As part of this corporate commitment we work towards driving innovation to overcome healthcare challenges of the present and the future in a bid to improve people’s health and wellbeing.
Oncology is a crucial medical practice that is a core element of the healthcare landscape. Currently 1 in 3 women and 1 in 2 men will be diagnosed with cancer in their lifetime. Philips is constantly looking at ways to detect cancer earlier and diagnose it more precisely, enabling our customers to take a personalized approach and give the patient the best possible care.
Our commitment is to provide technologies and support that enable accurate registration of anatomical and biological data, a comprehensive assessment of disease characteristics as well as data integration into the care cycle workflow to allow for effective treatment decisions.
We continue to invest in oncology research with the aim of creating a healthier future for all.
At Philips we believe in an integrated healthcare approach, featuring the delivery of world-class solutions, with the ultimate aim of improving patient experience and outcomes. Our focus is to deliver value throughout the complete continuum of care: from disease prevention to screening and diagnosis through to treatment, monitoring and health management, allowing us to transform how care is delivered and experienced, helping to meet patient needs more effectively.
Philips Research has over 100 years at the forefront of medical care, with numerous patents in the medical technology category. Innovations in our portfolio include the first X-ray tubes made for the professional market in 1918, followed by the introduction of the first digital radiography system in the early 1990s, the introduction of the first 1.5T and 3.0T compact MRI systems and recently the first digital PET/CT.
Discover UroNav – image-guided prostate biopsies at Arab Health 2020.
to detect cancer earlier and diagnose it more precisely, enabling our customers to take a personalized approach and give the patient the best possible treatment outcomes.
Accurate, early detection
to save lives
Cancer Screening Solution
Cancer accounts for more than 10% of all deaths in most Middle Eastern countries. However, the region’s ageing and growing population will result in an increasing incidence of cancer by 2030.
As a recognized leader in the healthcare industry, Philips acknowledges the importance of screening to avoid “premature deaths” and promote a better quality of life.
With over 400 employees in the Middle East, an established professional representation and a dedicated Oncology team, Philips brings a wealth of experience to any cancer screening program. Philips Health Systems enable healthcare organizations to encourage, identify and screen women and men throughout the country. Our comprehensive integrated solution includes a locally- relevant and culturally sensitive public awareness program, the delivery of a quality and safety driven diagnostic service program, and an advanced clinical and IT infrastructure.
Cancer screening program
Diagnosis Philips comprehensive solution for an Oncology Center
In Philips Middle East, we are building upon our capabilities and customer’s needs based on our deep understanding of the clinical pathway of cancer patients as shown in the illustration (below):
Based on this clinical pathway, we have developed an oncology solution that is built on five pillars that are necessary to improve oncology services, provide excellent healthcare and strives to achieve better outcomes for patients.
By clicking on the link, you will be leaving the official Royal Philips Healthcare ("Philips") website. Any links to third-party websites that may appear on this site are provided only for your convenience and in no way represent any affiliation or endorsement of the information provided on those linked websites. Philips makes no representations or warranties of any kind with regard to any third-party websites or the information contained therein.